Gastrointestinal Neoplasm Clinical Trial
Official title:
Prospective Single Centre, Post Market, Randomized Controlled Trial to Demonstrate Feasibility, Safety and Efficacy, of a Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection
The goal of this prospective, single centre, 1:1, Post Market, randomized controlled, Investigator Initiated trial, is to compare the feasibility, safety efficacy, and clinical outcomes of colonic endoscopic submucosal dissection (ESD) utilizing a novel rigidizing overtube called Pathfinder® Endoscope Overtube (Neptune Medical, Burlingame California, USA) device in comparison to conventional ESD. The research team hypothesize that with utilizing a novel rigidizing overtube the procedure time including dissection speed and closure time will be faster due to higher scope stability and greater control over the scope tip. Subsequently, the investigators anticipate lower immediate or delayed adverse events.
Status | Not yet recruiting |
Enrollment | 66 |
Est. completion date | July 31, 2025 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria: - Patient is = 22 years old. - Patients can provide written informed consent. - Patient is referred for ESD procedure of colonic neoplastic lesions and with one of the following criteria: A - Lesions with prior resection or with scar at any size proximal to the sigmoid colon. B - Granular lateral spreading tumors (GLST) more than 30mm. C - Non granular lateral spreading tumors (NGLST) more than 20 mm. D - Any suspected submucosal invasion such as Paris classification II a +II or lesions with positive non lifting sign. Exclusion Criteria: - Patient refused and/or unable to provide written informed consent. - Patient is a pregnant or nursing woman. - Lesions with morphology: pedunculated type (Paris Ip, Ips). - Lesions located within the sigmoid colon or rectum. - Lesions involving appendiceal orifice or ileocecal valve |
Country | Name | City | State |
---|---|---|---|
United States | Baylor College of Medicine | Houston | Texas |
United States | Baylor St. Lukes Medical Center (BSLMC) | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Baylor College of Medicine | Neptune Medical, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Procedure Time | Total Procedure Time to perform ESD from scope in to scope out | Day 1 (procedure day) | |
Secondary | Navigation Time | Total time needed to reach the lesion | Day 1 (procedure day) | |
Secondary | Technical Success | The ability to complete the entire resection using the device without the need to change to a different tool. This will be marked as either 'yes' or 'no' on the collection report form following the procedure by the research team. | Day 1 (procedure day) | |
Secondary | Clinical Success | The ability of endoscopic removal of polyps without changing the initial resection intent. This will be marked as either 'yes' or 'no' on the collection report form following the procedure by the research team. | Day 1 (procedure day) | |
Secondary | En-bloc, R0, and curative resection rates | As collected and measured for each group | Day 1 (procedure day) | |
Secondary | Dissection speed during colonic ESD as calculated by | cm^2/hr | Day 1 (procedure day) | |
Secondary | Closure time | Time needed to close area following endoscopic resection | Day 1 (procedure day) | |
Secondary | Sedation time | Total time patient spent under anesthesia | Day 1 (procedure day) | |
Secondary | User-feedback post-procedure | Subjective assessment of the degree of difficulty reaching the lesion based on a brief questionnaire given to the endoscopist following the procedure. | Day 1 (procedure day) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Approved for marketing |
NCT00094029 -
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
|
N/A | |
Completed |
NCT01621295 -
Assessing the Patient Experience in Cancer Care
|
N/A | |
Withdrawn |
NCT03538613 -
Study of People With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
|
Phase 1/Phase 2 | |
Completed |
NCT02785783 -
Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection
|
N/A | |
Completed |
NCT05172635 -
Primary Tumour Response to Induction Chemotherapy in Synchronously Metastasized Colorectal Cancer
|
||
Completed |
NCT01129310 -
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.
|
Phase 2 | |
Completed |
NCT03411915 -
A Study of XmAb®18087 in Subjects With NET and GIST
|
Phase 1 | |
Completed |
NCT00052962 -
Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis
|
Phase 3 | |
Recruiting |
NCT06159634 -
Traction vs. No Traction in Colonic ESD
|
N/A | |
Withdrawn |
NCT00640692 -
Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial
|
||
Completed |
NCT05320029 -
Disposable Powered Articulating Linear Cutter Stapler in Gastrointestinal Tissue Cutting and Anastomosis
|
N/A | |
Completed |
NCT00465725 -
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
|
Phase 1 |